Agios Pharmaceuticals | AGIO - Equity Capital And Reserves


Agios Pharmaceuticals reported $1.28B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Astellas Pharma JPY 1.76T 150.69B Dec/2025
AstraZeneca USD 45.89B 1.17B Sep/2025
Bayer EUR 29.7B 799M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Exelixis USD 2.16B 127.16M Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 9.33B 69M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025